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8INTRODUCTION
Restenosis after percutaneous transluminal coronary angioplasty operations occurs in
30-40% of patients within 3-6 moths (Holmes et al., 1984). Chronic rejection remains
the most important cause of late transplant loss in heart and kidney transplantations
(Cecka and Terasaski, 1993). The biomechanisms of these vasculoproliferative
processes still remain largely unknown, and there is no treatment for such diseases.
Neointimal formation leading to occlusion of arteries is the principal pathogenic
mechanism underlying atherosclerosis, restenosis after angioplasty operations and
transplant vascular sclerosis. The common feature in all these fibrointimal dysplasias is
inappropriate neointimal smooth muscle cell (SMC) proliferation leading finally to
occlusion of the artery. Several peptide growth factors have been identified in the
formation of classical atherosclerotic (Ross, 1991), transplantation arteriosclerotic
(Gordon, 1992) and restenotic (Cercek et al., 1991; Libby et al., 1992) plaques by
inducing migration and proliferation of SMC. In addition to migration and proliferation,
programmed cell death is involved in maintaining cell numbers in vascular wall layers
(Björkerud and Björkerud, 1997). More recently, inflammation has been considered to
be an important etiologic factor in neointimal lesion formation (Zhou et al., 1996).
Inflammatory cells are abundantly found in atherosclerotic plaques and in the blood
vessels of organ transplants, where they are believed to induce cytokine and adhesion
molecule expression leading to the progression of disease.
This study focuses on the mechanism of neointimal formation in experimental rat
models of endothelial injury caused either by prolonged cold ischemia time or a balloon
catheter, and the regulatory roles of insulin-like growth factor 1 (IGF-1) and platelet-
derived growth factor (PDGF) on the formation of these lesions.
9REVIEW OF THE LITERATURE
1. Vasculoproliferative disorders
1.1. Atherosclerosis
Atherosclerosis is a chronic inflammatory, fibroproliferative disorder causing luminal
narrowing of arteries and leading to oxygen insufficiency in peripheral organs. Our
understanding of the pathogenesis of atherosclerosis has widely increased in the past
decades (Ross et al., 1984, 1986, 1993, 1995). Hyperlipidemia, hypertension, glucose
intolerance, and smoking are now commonly accepted as risk factors for atherosclerosis.
So far, lipid-lowering treatment has been shown to be effective in the primary (Kjekshus
and Pedersen, 1995; Sheperd et al., 1995) and secondary (Sacks et al., 1996) prevention
of coronary events, such as myocardial infarction. Also, antiplatelet therapy has been
shown clinically effective in the primary prevention of vascular occlusion (Antiplatelet
Trialists´ Collaboration, 1994a), as well as in maintaining vascular patency after
restenosis (Antiplatelet Trialists´ Collaboration, 1994b). More recently, certain
inflammatory agents such as chlamydia pneumoniae (Kuo et al., 1993; Saikku et al.,
1988) or cytomegalovirus (Chiu et al., 1997; Speir et al., 1994) have been identified as
possible ethiologic factors for atherosclerosis and restenosis acting as local inducers of
inflammatory activation in arteries. Interestingly, also macrolide antibiotic treatment
effective on chlamydia pneumoniae infection, among others, has been shown in pilot
studies to be effective in the secondary prevention of cardiovascular events (Gupta et al.,
1997), while other prevention forms are being pursued.
1.2. Restenosis
Percutaneous transluminal coronary angioplasty (PTCA) is an effective noninvasive
procedure for coronary revascularization relieving symptoms due to coronary
arterioclerosis. However, restenosis after coronary angioplasty limits the long-term
success of PTCA. The restenosis rate after angioplasty to stenosis or total occlusion of
coronary arteries ranges from 30 to 40% (Holmes et al., 1984; Gruentzig et al., 1987),
despite multiple preventive attempts with pharmacological or mechanical means.
Restenosis is a hyperplastic, pathologic reaction involving SMC migration and
proliferation, extracellular matrix formation and remodelling of the arterial wall leading
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finally to reocclusion of the enlarged artery (Haudenschild, 1993). Similarly to early,
fibrous atheromas, human restenotic lesions consist mainly of fibrocellular tissue
(Virmani et al., 1994).  Injury to endothelial and SMC caused by the angioplasty
dilatation catheter followed by a proliferative response is believed to precede vascular
remodelling and occlusion (Austin et al., 1985). So far, the mechanism and risk factors
for restenosis remain largely unknown, and no effective treatment exists for restenosis.
Some studies suggest (Tschopl et al., 1997), that high procoagulant factrors after
angioplasty are risk factors for restenosis, and antiplatelet therapy is highly efficient in
the reduction of vascular occlusion after angioplasty (Antiplatelet
Trialists´Collaboration, 1994b). Also, promising preliminary results have been obtained
with the antiproliferative agents such as competitive inhibitor of PDGF,
triazolopyrimidine (Maresta et al., 1994) and angiopeptin (Emanuelsson et al., 1995).
Angiopeptin is believed to be a suppressor of local growth factor production, and thus
inhibit SMC proliferation (Häyry et al., 1993a).
1.3. Transplant arteriosclerosis
Chronic rejection or transplant arteriosclerosis remains the most important cause of late
transplant loss in heart and kidney transplantations (Cecka and Terasaski, 1993). The
lesions in transplantation arteriosclerosis resemble in their consistence the lesions of
classical atherosclerosis (Billingham, 1992; Häyry et al., 1993b) although intimal
thickening is concentric in comparison to the eccentric neointimal lesions in classical
atherosclerosis, and calcification usually never occurs. Risk factors for chronic rejection
are somewhat similar to the risk factors for atherosclerosis mentioned above. Apart from
these, prolonged cold ischemia time and the generation of free oxygen radicals have
been suggested to be risk factors for chronic rejection (Wanders et al., 1995). The
generation of free radicals during reperfusion is a likely mechanism leading to
endothelial damage and SMC replication in the arterial intima (Yilmaz, 1992; Flitter,
1993; Ward and Mc Carthy, 1994). Free oxygen radical scavengers, such as superoxide
dismutase enzyme or antioxidant therapy have been considered as treatments for
reperfusion injury (Land et al., 1994).
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2. Smooth muscle cells in the pathogenesis of arteriosclerosis and restenosis
2.1. Experimental models for studying smooth muscle cell migration and proliferation in
the pathogenesis of arteriosclerosis and restenosis
Rat carotid and aortic endothelial denudation are widely used models to study restenosis
of arteries after balloon angioplasty. One of the weaknesses of these models is that the
endothelial injury is induced on a normal vessel, whereas in man interventions are made
on vessels with pre-existing lesions (Schwartz et al., 1995). Also, no anticoagulant
therapy is usually given to rats subjected to ballooning injury, whereas anticoagulation is
an absolute requirement in humans whenever vascular interventions are performed.
Remodelling or recoil of vessels after angioplasty may be of great importance in the
pathogenesis of human restenosis, and therefore models in larger animals have been
developed (Carter et al., 1994; Geary et al., 1996). On the other hand, similar
proliferative patterns are seen in rodents and in primates (Geary et al., 1996). Two recent
experimental studies indicate that rodent models of repeated ballooning injury may be
more helpful than single injury models in determining the mechanisms of restenosis after
balloon angioplasty (Stadius et al., 1996; Koyama and Reidy, 1997). As in angioplasty
operations, ballooning in reinjury models is performed on an artery with a thickened
intimal layer (a diseased vessel), and the proliferative pattern of neointimal cells is
similar to the one seen in large animal models: a self-limited proliferative burst instead
of a sustained one seen in single injury models.
Cell cultures of arterial SMC allow studies on the mechanisms of the regulation of SMC
proliferation and migration in a closed system. Aortic transplantation between
histoincompatible rat strains is a useful and widely used model for studying acute and
chronic rejection in blood vessels (Mennander et al., 1991). In transplanted vessels,
endothelial injury occurs due to hypoxic/ischemic injury or acute rejection. After the
acute rejection has subsided in these grafts, transplanted vessels have the same
morphological features as injured vessels. Syngeneic transplants allow us to study the
effect of cold ischemia/reperfusion injury separately from the immunological events in
transplanted organs. Syngeneic rat aortic transplants subjected to prolonged cold
ischemia time resemble morphologically balloon injured aortas and have neointimal
lesions consisting mainly of SMC α-actin positive cells (Wanders et al., 1995). It is
likely that the mechanisms of lesion formation in all these models partially overlap.
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Therefore, therapeutic strategies that suppress SMC proliferation in any of these models
can be used in the treatment of the diseases with a similar pathogenesis.
2.2. Smooth muscle cell differentiation
Matrix metalloproteinase activity in the vessel wall is a requirement for extracellular
matrix degradation and SMC migration (Bendeck et al., 1994, 1996). Cytokines released
by inflammatory cells can induce matrix metalloproteinase expression and enhance SMC
migration (Galis et al., 1995). The plasminogen-plasmin system and the urokinase type
plasminogen inhibitor are rate-limiting regulators of metalloproteinase activity and cell
accumulation after endothelial injury (Lijnen et al., 1998), and the presence of
plasminogen activators is a requirement for optimal response to PDGF-induced
mitogenic signals (Herbert et al., 1997). Regardless of the primary cause of the
endothelial injury (i.e. accumulation of oxidized fat, mechanical and/or immunological
injury), the response to injury in the vascular wall leads to proliferation of SMC in the
medial and adventitial layers, migration of neoitimal SMC precursor cells to the intima,
and subsequent proliferation therein (Ross, 1993). Fibrous (early) atherosclerostic
lesions and restenotic lesions consist mainly of SMC (Fuster, 1997; Strong et al., 1997).
It has also been suggested that mononuclear or hematopoietic stem cells derived from
the circulation differentiate into intimal SMC (Bondjers et al., 1991).
Classically, it has been thought that SMC exist in two different phenotypes, of which the
"resting", "contractile" phenotype is located predominantly in the medial layer, whereas
the "synthetic" phenotype is the predominant SMC type in the neointimal lesions both in
experimental models and in humans (Thyberg et al., 1983). Lesion progression is
observed predominantly in SMC-rich lesions in comparison with macrophage-rich
lesions, and these regions have a high content of synthetic phenotype SMC (Strong et
al., 1997). Recent studies indicate that neointimal cells are in fact derived from different
subpopulations of certain types of medial/adventitial cells and not by differentiating
from any medial SMC (Cascells, 1992; Lemire et al., 1994; Frid et al., 1997). The gene
expression  of neointimal SMC resembles the one of SMC in developing blood vessels
(Majesky et al., 1992; Dupláa et al., 1997).
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2.3. Smooth muscle cell and macrophage apoptosis in arteriosclerosis and restenosis
Apoptosis, or programmed cell death is involved in the development of tissues and
maintaining stable cell numbers in the epithelia. Apoptotic SMC and macrophages are
found in atherosclerotic lesions, where they are believed to contribute to the risk of
plaque rupture in developed lesions (Björkerud and Björkerud, 1997) as well as
maintaining stable cell numbers in neointimal lesions (Isner et al., 1996; Kockx and
DeMeyer, 1996). Little is known about apoptosis in restenotic lesions, although some
studies suggest that apoptosis is even more frequent in advanced restenotic lesions than
in atherosclerotic lesions (Isner et al., 1996). It would therefore be plausible that
alterations in apoptotic activity could also lead to increase, or decrease, in plaque size
and luminal occlusion of arteries.
3. Role of inflammation in vascular lesion formation
3.1. Endothelial adhesion molecules
One of the first changes in atherosclerotic lesion formation is the adherence of
mononuclear inflammatory cells to the endothelial layer and the subsequent infiltration
of these cells into the subendothelial space (Ross, 1995). Increased levels of activated
leukocytes are present in the peripheral blood after coronary angioplasty, and a higher
level of leukocyte activation correlates with late clinical events (Mickelson et al., 1996).
The injured/regenerating endothelium directs the adherence of monocytes by expressing
adhesion molecules that bind to specific receptors in the mononuclear inflammatory
cells (Tanaka et al, 1993, 1994). Adhesion molecules are overexpressed in the
endothelium overlying atherosclerotic plaques (O´Brien et al., 1993a) or chronic
rejection -related vascular lesions (Koskinen and Lemström, 1997). Local inflammatory
factors induce the expression of adhesion molecules on endothelial cells (Couffinhal et
al., 1994). It is believed that these membrane glycoproteins mediate leukocyte rolling to
the vascular wall (Sakai et al., 1997). Firm adhesion of leukocytes to the vasculature is
further mediated by vascular cell adhesion molecule 1, VCAM-1, and intercellular
adhesion molecule 1, ICAM-1. Recent findings indicate that these adhesion molecules
are also expressed during SMC differentiation (Couffinhal et al., 1994; Dupláa et al.,
1997). The significance of adhesion molecule expression during SMC differentiation is
not known.
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3.2. Proinflammatory cytokines
As mentioned above, there is increasing evidence of a local immune response in the
pathogenesis of atherosclerosis. However, fewer reports exist concerning the
inflammatory nature of human restenotic lesions. Activated mononuclear inflammatory
cells infiltrating the vascular wall are capable of producing inflammatory mediators,
such as TNF−α and IL-1, which contribute to the local immune reaction and activation
of the vascular wall (Hancock et al., 1994). These cytokines are also produced by
proliferating SMC (Tanaka et al., 1996), and they have been shown to induce SMC
proliferation in vitro  (Thyberg et al., 1990; Casscells, 1991). Cytokines in turn induce
the expression of chemotactic and pro-proliferative peptide growth factors and their
receptors possibly initiate autocrine cycles leading to persistent SMC proliferation and
lesion progression (Raines et al., 1989; Battegay et al., 1990). Also, adhesion molecule
expression such as VCAM-1 and ICAM-1 expression are induced by these same
cytokines (Wang et al., 1994; Libby and Galis, 1995). However, the regulatory networks
of these complicated interactions are so far unknown.
3.3. Peptide growth factors
Several peptide growth factors contribute to the formation of atherosclerotic and
restenotic lesions (reviewed by Ross, 1991 and Cercek et al., 1991, respectively). The
same growth factors induce SMC proliferation in vitro  (Thyberg et al., 1990; Casscells,
1991), and are expressed by SMC (Casscells, 1991) or released from injured SMC
(Crowley et al., 1995). Elevated levels of mRNA transcripts of IGF-1 (Cercek et al.,
1990), EGF (Miano et al., 1993), PDGF A and B chains (Miano et al., 1993),
transforming growth factor-ß1, (TGF-ß1) (Majesky et al., 1991), and several others,
have been detected in the vascular wall after endothelial injury, and furthermore,
antibodies to PDGF (Ferns et al., 1991), basic fibroblast growth factor (Lindner and
Reidy, 1991), and TGF-ß1 (Kanzaki et al, 1995), prevent neointimal formation after
endothelial injury demonstrating that these growth factors are essential in this process.
The experiments in this study focus on the role of IGF-1 and PDGF in SMC
proliferation in vitro and neointimal formation in vivo in the rat arteries.
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3.4. IGF-1
IGF-1 is known as a major regulator of embryonic growth (Baker and Liu, 1993).
Previously known as somatomedin for its effects as the major mediator of growth
hormone actions, IGF-1 is abundant in the circulation and its action is regulated by six
binding proteins (reviewed by Jones and Clemmons, 1995). Most of the cellular events
of IGF-1 are mediated by its receptor, IGF-1R. It has recently become evident that IGF-1
is also an important regulator of proliferation of mesenchymal cells, including fibrobasts
and SMC. Upregulation of IGF-1 has been documented after ballooning injury (Cercek
et al., 1990). The optimal mitogenic responses to epidermal growth factor (EGF) and
PDGF require a functional IGF-1R (Pietrzkowski et al., 1992; Miura et al., 1994) and
IGF-1 and PDGF are known to act synergistically in the induction of cellular
proliferation (Clemmons, 1985), possibly through upregulation of IGF-1R expression
(Delafontaine et al., 1991; Rubini et al., 1994). Antisense oligonucleotides that inhibit
expression of IGF-1R inhibit thrombin, angiotensin II, and PDGF-induced mitogenesis
in vascular SMC (Delafontaine et al., 1996), indicating that the IGF-1R activation is a
rate limiting step in cell cycle progression (Baserga, 1993). More recently, it has been
shown that IGF-1R activation mediates chemotactic signaling in SMC (Bornfeldt et al.,
1994).
3.5. PDGF
PDGF were initially discovered as growth factors released from platelets at sites of
injury.They are now recognized to be produced also by macrophages and SMC in
atherosclerotic lesions, and they are known to be among the most potent SMC
chemoattractants and mitogens. There are two homologous PDGF polypeptides, the
PDGF-A chain and the PDGF-B chain, which are found as disulphide-linked dimers
PDGF-AA, -AB and -BB (Ross et al., 1986; Heldin and Westermarck, 1990). Two types
of PDGF receptor chains are known, the α-and ß-receptors (PDGF-Rα and PDGF-Rß).
PDGF-Rα binds all PDGF-isoforms, whereas the ß-receptor binds PDGF-BB with high
affinity and PDGF-AB with lower affinity, but does not bind PDGF-AA (Hart et al.,
1988). The binding of PDGF ligand to its receptor leads to dimerization of receptor
subunits followed by activation of the receptor protein tyrosine kinase and receptor
autophosphorylation (Heldin et al., 1989).
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The in vivo role of the PDGF-A chain and PDGFR-α are not yet known, but could be
linked to proliferation, as evidenced by colocalization of PDGF-A production and
cellular proliferation in human atherosclerotic plaques (Rekhter and Gordon, 1994) and
rat neointima (Majesky et al., 1990). Furthermore, in vitro studies suggest that PDGF-A
acts mainly as a mitogen for vascular cells (Koyama et al., 1994a), and may have
regulatory functions in relation to PDGF-Rß mediated signalling (Koyama et al., 1994b).
PDGF-BB is known as the most potent chemoattractant and mitogen to SMC
(Grotendorst et al., 1982; Heldin and Westermarck, 1990; Thyberg et al., 1990). Local
overexpression of the PDGF-B gene is accompanied by migration and proliferation of
SMC and thickening of uninjured arteries (Nabel et al, 1993) and administration of
PDGF protein leads to enhanced migration of cells in rat carotid artery (Jawien et al.,
1992). Inhibition of PDGF-Rß expression with antisense oligonucleotides dramatically
suppresses neointimal thickening in rat carotid artery (Sirois et al., 1997).
3.6. Regulation of local growth factor production
After endotelial injury, mononuclear inflammatory cells adhere to sites of injury. CD4+
T-cells express inflammatory cytokines such as interleukin-1 and tumour necrosis
factor-α, which in turn trigger SMC and macrophages to produce growth factors
creating an autokrine cycle of growth factor production and proliferation. Apart from
these paracrine factors, hormones regulate local growth factor production in the vascular
wall. Growth hormone is known as the major regulator of IGF-1 production in the liver.
Hypophysectomy decreases intimal SMC proliferation via downregulation of IGF-1
(Khorsandi et al, 1992). Somatostatin analogs, such as octreotide and lanreotide are
inhibitors of growth hormone/IGF-1 axis, and inhibit SMC proliferation in vitro (Grant
et al., 1994) and growth factor production in aortic transplats in vivo (Häyry et al.,
1993). Ocreotide downregulates IGF-1 levels in arteries after injury, but has no
significant effect on blood growth hormone levels (Yumi et al., 1997), indicating that
somatostatin or its analogs act as a local regulator of IGF-1 production. Recent findings
indicate that the estrogen receptor ß is a major regulator of neointimal proliferation
(Mäkelä et al., 1999). Estrogen has been shown to be inhibitory to growth factor-induced
proliferation. However, it is so far not known whether estrogen receptor ß regulates
growth factor production, or whether it regulates the cell cycle independently from
growth factor action.
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4. Intervention of growth factor action
4.1. General
The interference of gowth factor/receptor interaction may be a suitable therapeutic
means for the prevention of proliferative response to vascular injury. Several approaches
have been developed for the inhibition of growth factor/ligand interactions, such as the
inhibition of gene expression with antisense oligonucleotides  (Bennett and Schwartz,
1995) and transfection of cells using liposomal or viral vectors (Nabel et al., 1993, 1997;
Yonemitsu et al., 1997; ) or inactivation of growth factors with blocking antibodies
(Ferns et al., 1991; Lindner and Reidy, 1991; Wolf et al., 1994). However, these
approaches are relatively experimental and have many disadvantages when therapeutic
applications for humans are being developed.
4.2. Peptides and D-peptide analogs
One approach in rational drug design is to design and synthesize peptidic compounds
that mimic natural protein conformations. However, normal L-amino acids are rapidly
degraded by body proteases. D-amino acids are resistant to this proteolytic degradation
in body fluids and thus have longer half-lives  (Brady and Dodson, 1994). The
conformation of D-amino acids being a mirror image to normal body proteins render
them incapable of conformation-dependent interactions with body proteins. If, however,
synthesised in reverse order, D-peptidic analogs mimic the conformation of natural L-
peptides. With this approach, activation of CD4+ T cells (Jameson et al., 1994) or IGF-
1/IGF-1R (Pietrzkowski et al., 1992) interactions can be competitively inhibited. These
D-peptidic analogs may become important tools in studies of the pathogenesis of disease
processes and finding possible therapeutic applications.
4.3. Tyrosine kinase inhibitors
Promising tools for the inhibition of growth factor mediated signal transduction in the
cell are receptor tyrosine kinase inhibitors. Tyrosine kinases that are overactivated by a
disease process can be specifically inhibited, and systemic side effects thus can be
avoided. Individual receptor tyrosine kinase conformations in different receptor families
opens the possibility for the development of selective tyrosine kinase inhibitors
(Levitzki and Gazit, 1995; Levitzki, 1996). Nonselective tyrosine kinases have the
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disadvantage of inhibiting normal receptor tyrosine kinase-mediated growth thus
rendering them toxic when systemically administered. This problem can partially be
overcome by local administration (Kozai et al, 1997). However, the existence of highly
selective tyrosine kinase inhibitors i.e., for EGF receptor, PDGF-R (reviewed by
Kovalenko et al., 1997), and IGF-1R (Parrizas et al., 1997) may allow systemic
administration.
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AIMS
The hypothesis in this study was, that peptide growth factors are major regulators of
vascular SMC migration and proliferation. Since peptide growth factors are abundant in
tissue and circulation, their receptors are more likely regulators of local cellular events,
such as migration and proliferation of vascular SMC, and thus more specific targets for
therapy. The aims of this study were:
1. To study SMC proliferation, migration and apoptosis in the formation of neointimal
lesions in rat models of arteriosclerosis and restenosis.
2. To investgate the role of PDGF or IGF-1-induced receptor activaction in vascular
SMC migration and proliferation.
In order to study arteriosclerotic lesion formation, three experimental rat models were
used: syngeneic rat aortic transplantations, ballooning injury of the rat carotid artery, and
reinjury of the rat aorta. For inhibition of lesion growth induced by IGF-1, a D-peptide
analog of IGF-1, JB3 was used. For inhibition of PDGF-R activation, a tyrosine kinase
inhibitor, CGP 53716, and its water soluble derivative, CGP 57148B were used.
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METHODS
1. Experimental animals
Male Wistar/SD rats or inbred WF (AG-B2 RT 1u) or DA (AG-B4, RT1a) rats
purchased from the Laboratory Animal Centre,  University of Helsinki, Helsinki,
Finland were used for the studies. A permit for animal studies was approved by the
Municipal Government of Uusimaa (KUN 78). Laboratory rats were treated according to
the Finnish law on animal rights (9§ 777/85). All animals received humane care in
compliance with the principles of Laboratory Animal Care and the Guide for the Care
and Use of Laboratory Animals prepared and formulated by the National Institute of
Laboratory Animal Resources and published by the National Institutes of Health (NIH
Publication no. 86-23) and the European agreement for the use of experimental animals
in scientific research. The rats were anesthesised with chloralhydrate, 240 mg/kg ip., and
0.3 mg/kg sc. buprenorphine (Temgesic, Reckitt & Colman, Hull, England) was used for
postoperative pain relief. A permit for the use of chloral hydrate anesthesia was received
from the county veterinarian. The basic diet of the animals was pellets (Altromin N:o.
1314, Standard diet, Chr. Petersen A/S, Ringsted, Denmark) and they were given tap
water.
2. Rat models of arteriosclerosis and restenosis
2.1. Ischemia-induced injury in the rat aorta
For studies on cold-ischemia induced arteriosclerosis, the rat aortic transplantation
model of inbred DA rat strain was used. The surgical procedure was performed as
described by Mennander et al. (1991). The descending thoracic aorta was excised,
perfused with phosphate buffered saline and used as a transplant. The graft was sutured
into a heterotopic position below the renal arteries in the abdominal aorta. Syngeneic
grafts with prolonged cold ischemia were stored for 24 h in 4°C phosphate buffered
saline  before transplantation. The grafts were removed at 1, 2, 3 or 6 mo after
transplantation. Some grafts were analysed immediately after cold preservation.
Syngeneic transplantations with short ischemia times (5-15 min) served as controls.
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2.2. Rat carotid artery denudation
The left common carotid artery was denuded of endothelium by the intraluminal passage
of a 2 French Fogarty arterial embolectomy catheter (Baxter Healthcare Corporation,
Santa Ana, CA) introduced through the external carotid artery as described (Clowes et
al., 1983). The catheter was passed three times with the balloon inflated with 0.2 ml air.
The external carotid artery was ligated and the wound was closed.
2.3. Rat aortic denudation and reinjury of the rat aorta
The thoracic aorta was denuded of endothelium using a 2 French Fogarty arterial
embolectomy catheter (Baxter Healthcare Corporation). The catheter was introduced
into the thoracic aorta via the left iliac artery, inflated with 0.2 ml air, and passed five
times to remove the endothelium. The iliac artery was ligated after this procedure. When
a second injury was produced, the catheter was introduced to the aorta upstream from
the initial ligature, and the procedure was repeated in a similar manner as for the first
injury. The animals were harvested at  0, 3, 7 and 14 d after both injuries and their
tissues were processed for histology and immunohistochemistry. No anticoagulant
therapy was given to the rats.
3. Semiquantitative RT-PCR
3.1. RNA isolation
Biopsies taken from blood vessels were snap-frozen immediately in liquid nitrogen.
Total cellular RNA was extracted by the guanidium isothiocyanate method (Davis et al,
1986). Tissues were homogenized (Ultra-turrax, Janke & Kunkel, Staufen, Germany) in
3 ml guanidium-isothiocyanate buffer. The homogenate was pipetted on 2 ml of 5.7 M
CsCl buffer in polyallomer tubes (Beckman Instruments, Fullerton, CA). The tubes were
centrifuged at 32 000 RPM for 21 h. After centrifugation, the samples were resuspended
in TES buffer (10 mM Tris, pH 7.4, 5 mM EDTA, pH 7.4, 1% SDS) and phenol purified
three times. Aqueous RNA was precipitated with 3 molar sodium acetate and the optical
density was measured spectrophotomerically.
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3.2. RT-PCR
First-strand cDNA was generated from 1 µg RNA in a 20 µL volume using commercial
Perkin Elmer Cetus protocol (Norwalk, Conn.). One µl of the reverse transcription
reaction mix was amplified with primers specific for rat IGF-1, PDGF-B, EGF, TGF-ß1,
acidic and basic fibroblast growth factors in a total volume of 50 µl. The primer and
probe sequences used are shown in paper II. The PCR-product was added to PCR-buffer
(500 mM, Tris, pH 8.8, 15 mM MgCl2, 150 mM NH4SO4, 0.1% gelatin, 1 % TRITON-
X-100) using 0.2 mM of each nucleotide and 1 µM of each primer and 2.5 U Taq DNA-
polymerase. The samples were processed for  25-28 cycles each with the following
thermal parameters: 94 oC, 1 min, 57oC, 1 min and 72oC, 2 min. Glyseraldehyde-
phosphate dehydrogenase (GAPDH) primers were used as the control PCR. The samples
were electrophoresed on an agarose gel and Southern blotted to a nylon membrane.
Radiolabeled probes specific for each growth factor were hybridized to the membrane
and autoradiography was performed. The intensity of hybridization signals was
measured with densitometry (Electrophoresis Data Center, Helena Laboratories,
Beamont, TX).
4. Histological evaluation
4.1. Determination of cell number
Normal, noninjured rat arteries do not have a cellular neointimal layer, as do humans.
The intima in intact rat arteries consist only of the internal elastic lamina extracellular
matrix covered by the endothelial cell layer. For evaluation of morphological changes,
aortic and carotid cross sections were fixed in 3% paraformaldehyde (pH 7.4),
embedded in paraffin for sectioning, and stained with Mayer´s haematoxylin and eosin
(HE). For evaluation of intimal and medial thickness and cell number in syngeneic
aortic transplants, a microscope ocular with a 0.02 mm grid was used. The data was
expressed as point score units, i.e., the mean number of points falling over a given
anatomical area using 8 straight cross-sectional lines. The absolute number of cells in
the intima, media and adventitia were calculated from paraffin cross sections at 400 x
magnification.
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4.2. Morphometric analysis
To quantitate neointimal/medial areas at the end of observations in the aortic denudation
specimens, the intimal and medial areas were quantitated using Macintosh NIH image
software. The picture from the microscope was transferred to a screen with an Olympus
video microscope using 100x magnification. The areas inside the internal elastic lamina,
the external elastic lamina, and of the aortic lumen were measured, and intimal and
medial areas, and intima/media area ratio were calculated from these values.
4.3. Immunohistochemistry
Serial frozen sections (4-6 µm) were air-dried on silane coated slides, fixed in acetone at
-20°C for 20 min, and stored at -20°C until used. Before immunostaining, the slides
were refixed with chloroform and then air-dried. After incubation with appropriate 1.5%
nonimmune serum (Vector Laboratories, Burlingame, CA) for monoclonal or polyclonal
antibodies, frozen sections were incubated with a mouse monoclonal antibody at room
temperature for 30 to 60 min or with a rabbit polyclonal antibody at +4°C for 12 h. The
primary antibodies were diluted in PBS with 1% BSA and appropriate 3% nonimmune
serum. With intervening washes in Tris-buffered saline, the following steps were
performed: biotinylated horse anti-mouse or goat anti-rabbit rat-absorbed antibodies at
room temperature for 30 min; avidin-biotinylated horse-radish complex (Vectastain
Elite ABC Kit, Vector Laboratories) in PBS at room temperature for 30 min; the
reaction was revealed by chromogen 3-amino-9-ethylcarbazole (AEC; Sigma)
containing 0.1% hydrogen peroxidase, yielding a brown-red reaction product. The
coverslips were counterstained with haematoxylin and mounted. The antibodies used are
presented in Table 1.
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Table 1. Mono- and polyclonal antibodies used to detect cell type, activation state,
adhesion molecules and PDGF ligands/receptors.
__________________________________________________________________
Antibody against Dilution Manufacturer
_________________________________________________________________________________________________
mouse ED3 (activated MF) 1:200 Serotec, Oxford,
monoclonal UK
CD4+ T-cells 1:100 W3/25, Sera-lab,
Sussex, UK
CD8+ T-cells 1:100 OX8, Sera-Lab
Natural killer cells 1:100 3.2.3.*
Class II 1:100 OX6; Sera-lab
ICAM-1 1:100 CD 54, Seikagu,
Tokyo, Japan
LFA-1, lymphocyte 1:100 Seikagu
function associated
antigen 1
VLA-4 very late 1:100 Seikagu
antigen 4
VCAM-1 1:100 Biogen, Cambridge,
MA **
P-selectin (CD62) 1:100 Pharmingen,
Hamburg, Germany
α-actin 1:500 Bio-Makor,
Revohot, Israel
rabbit PDGF-AA 1:100 ZP214, Genzyme,
polyclonal Cambridge, MA
PDGF-BB 1:100 ZP215, Genzyme
PDGF-Ra 1:100 sc-338, Santa Cruz
Biotecnology,
PDGF-Rβ 1:100 sc-339; Santa Cruz
Biotechnology,
_________________________________________________________________
* A generous gift from Dr. William H Chambers, Pittsburgh Cancer instititute,
Pittsburg, P.A
** A generous gift from Dr Roy Lobb, Biogen, Cambridge, MA
Controls were performed using the same immunoglobulin concentrations of species and
isotype-matched antibodies: mouse monoclonal IgG1 antibody (catalog No. X931;
Dako, Glostrup, Denmark) and rabbit polyclonal immunoglobulin fraction (catalog No.
X936; Dako) for monoclonal and polyclonal antibodies, respectively. Additional
specifity controls for PDGF ligand and receptor staining involved the use of a working
dilution of the polyclonal antibody after overnight incubation with a 10 to 20-molar
excess of recombinant peptide (for Santa Cruz's antibodies). None of these control
staining showed any immunoreactivity.
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4.4. Quantitation of immunohistochemistry
For inflammatory cell and adhesion molecule staining, positive cells in each cross
section were counted separately from the advential, medial, and intimal layers. The
intensity of immunohistochemical staining for PDGF receptors and ligands was scored
from 0 to 3 as follows: 0, no visible staining, 1, faint staining, 2, mild to moderate
staining, and 3, intense staining.
5. Cell kinetics studies in vivo
5.1. Quantitation of smooth muscle cell proliferation in vivo
Tritiated thymidine (3H-TdR, Amersham International plc, Amersham, UK) was
administered by iv. injection via the femoral vein to rats, at a dose of 50 µCi/100 g 3 h
prior to sacrifice. Histology was processed from paraffin cross sections and emulsion
film autoradiography (Ilford L-4; Ilford, Mobberley, Cheshire, England) was performed.
Alternatively, thymidine analog Bromodeoxyuridine (BrdU, Zymed Laboratories, San
Francisco, CA) labeling was used for quantitation of cellular proliferation. The rats
received 0.3 ml iv. BrdU labeling reagent according to the manufacturer´s instructions
three to six hours before sacrifice. Proliferating cells, which had incorporated BrdU
were visualized by immunoperoxidase staining made from paraffin cross sections. The
number of labeled nuclei was counted separately in the intima, media and adventitia of
the sections.
5.2. Apoptosis assays
Programmed cell death was quantitated from rat aortic paraffin sections that had
undergone one or two ballooning injuries. The sections were deparaffinized in xylene
and alcohol and stained using the terminal dideoxynucleotidetransferase (TdT)-mediated
digoxigenin-ddUTP nick end labelling (TUNEL) procedure. Reagents were purchased
from Boehringer Mannheim (Mannheim, Germany). The deparaffinized sections were
permeabilized by microwave treatment (for 5+3 min, in 10 mM citric acid), followed by
preincubation in 5 mM CoCl2 TdT buffer for 10 min (37°C) and the digoxigenin-
ddUTP labelling of the nicked DNA ends by TdT for 60 min (37°C, 5 mM CoCl2, 5
mM TdT-buffer, 0.23 mM ddATP, 0.13 mM dig-ddUTP, 0.58U/µl TdT). To detect the
labeled cells, the sections were blocked by 2% blocking reagent in 150 mM NaCl, 100
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mM Tris-HCl, and then treated with anti-digoxigenin Fab fragments, 0.19 U/ml in
blocking buffer, 37˚C, 60 min. Finally, the sections were incubated with a peroxidase
dye, NBT/BCIP solution in 67% DMSO, for up to 60 min. Nuclear counterstaining with
hematoxylin was performed. A similar procedure without the Tdt-treatment was used as
a negative control for every sample. Positive cell numbers were calculated separately
from the intimal and medial layers from nondenuded control specimens and at 4 h, 3 and
7 days after the first and 4 h and 3 days after the second injury. The percentage of
apoptotic cells was calculated from the total number of TUNEL+ cells compared to the
total number of cells/cross section.
5.3. Quantitation of SMC migration in vivo
Based on the finding that the first SMC appear in the neointima 4 days after denudation
of rat carotid artery, the in vivo  migration rate of SMC was estimated using histological
cross sections of denuded carotid specimens (Figure 1). BrdU labeling at different time
periods after endothelial injury was used to exclude overestimation of the migration rate
due to cell proliferation. For quantitation of SMC proliferation before any migrated cells
are seen in the intima, 0.1 ml of BrdU-labeling reagent (Zymed) was administered i.v.
every 12 h during postoperative hours 0-72 (a total of six x 0.1 ml). For quantitation of
proliferation during the initial wave of migration, the rats received 0.1 ml BrdU labeling
reagent three times at 8 h intervals during postoperative hours 72-96. For quantitation of
proliferation at the end of the initial wave of migration, a third group of rats received a
0.3 ml BrdU pulse three hours before sacrifice. Using BrdU labeling during the initial
wave of migration of SMC from the media into the neointima (72-96 h after injury), a
reasonable estimate of the migration rate can be made (Calderón et al., unpublished
observations).
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Figure 1. In vivo migration assay. 72 h after carotid denudation, no cells are seen on the
luminal side of the internal elastic lamina. 96 h after injury, the first cells appear in the
neointima. This "window" was used to quantitate migration of α-actin positive cells.
6. Cell culture studies
6.1. Primary smooth muscle cell cultures
Primary aortic SMC were isolated from 9 to 11-day-old DA (AG-B4, RT1a) rat aortas
using a method modified from that of Thyberg et al. (Thyberg et al., 1983). The aortas
were opened longitudinally and the endothelial layer was gently scraped off. The
adventitia and media were separated, and the medial layer was digested with 0.1%
collagenase and DNAse in PBS for 30 min at +37°C. The cells were centrifuged,
suspended in culture medium and allowed to attach to plastic flasks. Primary cells were
used at passage 2-6 for the experiments. The cells were subcultured in Dulbecco´s
modified eagle´s medium (DMEM, Gibco, Paisley, Scotland) supplemented with 10%
fetal calf serum (FCS), 2 M glutamine, 100 M streptomycin and 100 IU/ml penicillin.
For identification, the cells were grown on glass coverslips and stained for SMC α-actin
(as described above).
6.2. Rat coronary cell line
Alternatively, a rat coronary SMC line from Dr. C. A. Diglio (Wayne State University,
Detroit, MI) kindly provided by Dr Dariusz Leszczynski from the State Department of
Radiation Hazard, Helsinki, were used for the in vitro experiments. The cells were
subcultured in DMEM supplemented with 10% FCS, 2 mmol/ml glutamine, 100
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mmol/ml streptomycin and 100 IU/ml penicillin. For identification, the cells were grown
on glass coverslips and stained for SMC α-actin.
6.3. Quantitation of smooth muscle cell proliferation in vitro
Subcultures of SMC isolated from rat coronary artery, or primary cultures of baby rat
aortic SMC were used. Cells were cultured in Dulbecco´s modified eagles medium
supplemented with 10% FCS. For the experiments, cells were trypsinized and 8000 cells
were seeded on 96-well multidishes (Nunc, Roskilde, Denmark) or culture slide
microwells (Falcon, Beckton Dickinson, New Jersey) at a concentration of 40 000
cells/ml, and allowed to adhere to the wells for 24 h. After 72 h of serum starvation,
quiescent cells were stimulated with growth factors (PDGF, IGF-1, EGF or bFGF) in
serum-free medium for 24 or 42 h. The number of cells was quantitated by counting the
cells microscopically (from culture slides) or by measuring Tritiated thymidine (3H-
TdR; Amersham International plc, Amersham, UK) incorporation. Alternatively, SMC
were seeded in 96-well multidishes (8000 cells/well) in full culture medium
supplemented with 10% FCS. The cells were exposed daily to 1 µCi/ml of 3H-TdR or
tritium-labeled glycine (3H-glycine; NEN Chemicals, Boston, MA) for 24 h to
quantitate DNA and protein synthesis, respectively.
6.4. Quantitation of SMC migration in vitro
Migration was  quantitated using Transwell culture chambers. SMC (one million/ ml)
were seeded in the upper chamber, and the chemoattractant was added to the lower
chamber. After an appropriate time (4-24 hours) the cells that had migrated to the lower
side of the filter were fixed in methanol (+4°C), stained, and counted microscopically.
6.5. Tyrosine kinase assays
For measurement of PDGF-R tyrosine phosphorylation, Swiss 3T3 cells provided by Dr.
G. Thomas (Friedrich-Miesher Institute, Basel, Switzerland) were used. Confluent cells
were incubated for 90 min with CGP 53716 and PDGF-AA or PDGF-BB for 10 min.
Cell lysate proteins were analysed by Western blotting using anti-phosphotyrosine
antibodies. For measurement of IGF-1R phosphorylation, primary rat SMC were serum
starved overnight, stimulated with 20 ng/ml IGF-1 and immunoprecipitated with anti-
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phosphotyrosine antibodies. Bound antibodies were detected using the ECL Western
blotting system from Amersham (Buckinghamshire, UK).
7. Drug administration and dosages
7.1. Recombinant human superoxide dismutase
Free radical scavenger recombinant human superoxide dismutase (rh-SOD) was
administered to rats transplanted with a syngeneic graft subjected to cold ischemia in
order to prevent reperfusion injury. administration of Rh-SOD was performed exactly as
in a previous study with human kidney allografts, where 200 mg (approximately 3
mg/kg) of rh-SOD was given intravenously during 10 minutes of graft reperfusion (Land
et al., 1994). Rh-SOD (Liposome Company, Princeton, NJ) was dissolved in PBS and
given 3 mg/kg i.v. in a lumbar vein. The infusion was started one minute before
reperfusing the graft and continued for ten minutes. Control rats were given a PBS-
infusion.
7.2. D-peptide analogs
The D-amino acid peptide JB3 (C-S-K-A-P-K-L-P-A-A-Y-C) was synthesized using
standard solid-phase techniques at the Jefferson Cancer Institute, Thomas Jefferson
University, Philadelphia as previously described by Pietrzkowski et al. and sufficient
quantities for the experiment were provided by Raggio-Italgene, Rome, Italy. Before rat
carotid denudation, 0.3 µg of JB3 was administrated s.c., and the remaining JB3 was
given via Alzet mini-pumps (Alzet Corp., Palo Alto, CA) at the indicated dose rate for a
period of 14 days. Four dosage rates of 10, 30, 100 and 300 µg/kg/day were given to
individual rat groups, with at least five rats in each group. The impact of drug
administration was compared to similarly operated rats receiving only diluent (saline).
For in vitro assays, JB3 was added to 10% FCS medium or to serum-free medium
supplemented with PDGF-BB at different concentrations (0.01-10 µg/ml).
7.3. Tyrosine kinase inhibitors of PDGF-R
Selective tyrosine kinase inhibitors CGP 53716 and CGP 57148B were synthezised by
Novartis pharmaceuticals, Basel, Switzerland). Both compounds were administered in
vivo at the same dose of 50 mg/kg/day. For in vivo studies, water-insoluble CGP 53716
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was dissolved in dimethyl suphoxide at a concentration of 200 mg/ml and diluted
thereafter 1:20 with 1% Tween in 0.9% NaCl. After sonication a homogenous solution
was obtained. Stock solutions and dilutions were prepared daily prior to administration.
This stock solution was diluted further in cell culture medium and used for the
experiments at concentrations of 10-0.1 µM. A water soluble derivative of CGP 53716;
CGP 57148B was dissolved in distilled water and administered orally once daily at a
dose of 50 mg/kg/day. For in vitro studies, a 10 mM stock solution in DMSO (CGP
53716) or distilled water (CGP 57148B) was prepared. These stock solutions were
diluted in cell culture medium, and used for the experiments at concentrations of 10-0.1
µM.
8. Statistical methods
In general, nonparametric tests were used for evaluation of statistical significance.
Nonparametric tests were chosen because the requirement of normal distribution in
nonparametric tests was usually not fulfilled due to a relatively small sample size. For
evaluation of statistical significance between two treatment groups, Mann-Whitney U
test was used. For evaluation of statistical significance between several groups, a
combination of the nonparametric Kruskall Wallis test and Dunn test, or analysis of
variance were used.
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RESULTS
1. Lesion formation in rat arteries after injury
1.1. Cold-ischemia-induced arteriosclerosis (I)
Syngeneic DA-DA aortic transplants with prolonged cold ischemia time were stored for
24 h in 4° PBS before transplantation. Control grafts were transplanted with minimal
ischemia times (5-15 min). The grafts were removed and analysed 0 h, 1, 2, 3 or 6 mo
after transplantation.
Immediately after cold preservation, the grafts resembled normal aortas with the
exception of an apparent reduction in endothelial cell numbers. Medial smooth muscle
cells were present at that time. However, already after 1 mo post transplantation, severe
loss in medial cell number (medial necrosis) was observed, which progressed for 3 mo
and was not restored after 6 mo of observation. Slight medial cell loss was observed in
the control group with a short ischemia time. Severe increase in neointimal cell numbers
was observed already at 1 mo after transplantation in the prolonged cold ischemia group,
whereas no significant increase in intimal cell number was observed in the control
group.
In order to study the possible growth factors mediating neointimal formation and
remodelling after prolonged cold ischemia time, semiquantitative PCR for known
inducers of SMC proliferation was performed on RNA isolated from these grafts. At this
time point, elevated levels of IGF-1 mRNA were detected, whereas levels of other
growth factors remained unchanged (PDGF-B, TGF--ß1, aFGF and bFGF) or decreased
(EGF).
One series of transplants were treated intravenously with rh-SOD in order to study
whether treatment with this free radical scavenger would prevent ischemia-induced
reperfusion injury and arteriosclerosis in aortic transplants. However, no effect on
medial necrosis or intimal thickening was observed with the treatment regimen used.
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1.2. Rat carotid artery ballooning injury  (II-III)
After rat carotid artery ballooning injury, an initial increase in the medial cell number on
day 2-3 was observed, which was followed by a gradual increase in intimal cell number
peaking on day 14 after injury. The first neoinimal cells appeared in the neointima from
72 h after injury onwards. The number of SMC appearing in the neointima during 0-96 h
was used as an estimate of the first wave of migrating cells after endothelial injury in the
rat.
Medial cell proliferation was measured by BrdU and 3H-TdR incorporation, on days 3-5
after injury. When labeled continously during the first 3 days, 16 % of all medial cells
had incorporated BrdU. Intimal cell proliferation peaked at day 7 after injury followed
by a decrease in the number of proliferating cells.
In order to study the possible growth factors mediating SMC proliferation and
neointimal formation after carotid ballooning injury, semiquantitative RT-PCR for
known inducers of SMC proliferation was performed on RNA isolated from carotid
arteries after injury. Elevated levels of IGF-1, PDGF-B and EGF were seen throughout
the observation time from day 5 to day 100, peaking 5-7 days after injury. A slight peak
increase in the level of TGF-ß1, acidic and and basic fibroblast growth factors were
found approximately on day 7 after injury.
1.3. Ballooning reinjury of the rat aorta (IV-V)
In order to study the effect of ballooning injury to the neointimal instead of the medial
SMC, a second ballooning injury was performed to rat thoracic aorta 14 d after the first
injury. The absolute number of cells, proliferating (BrdU positive) cells, inflammatory
cells and expression of adhesion molecules and PDGF receptors and ligands in different
vascular compartements were studied from aortas 0, 3, 7 and 14 d after the first and
second ballooning injury. Three days after the first injury, medial cell number increased,
whereas no change in medial cell number was seen after the second injury. After the first
injury, intimal cell number increased gradually. After the second injury a more
prominent and accelerated increase in intimal cells was seen. A peak in cellular
proliferation was seen in the medial layer at day 3 and in the intima at day 7 after the
first injury, whereas after the second injury, a pronounced proliferative peak was seen
already at day 3 after injury.
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TUNEL staining for apoptotic cells  of the critical time points of peak proliferation after
the first and second injuries (0, 7 and 3 days) was performed in order to study the level
of programmed cell death as a possible cause for the differential proliferative response
observed after first vs. second injuries. At days 3 and 7, the ratio of apoptotic cells was 5
and 6%, respectively (P=NS.) The number and percentage of apoptotic cells was
significantly higher 4 h after the first injury (23%) when compared to any other, but at 4
h after the second injury in the intima, it was only 2.6%, P<0.01.
Adhesion molecule VCAM-1 was upregulated in the medial and neointimal SMC during
the proliferative peaks after both the first and second injuries. P-selectin was expressed
in the regenerating endothelium after both injuries, whereas no P-selectin expression
was observed in noninjured arteries. An increase in the CD4+ T cells, NK cells and
activated mononuclear cells was observed in the adventitial layer after the first injury.
After the second injury, a prominent increase in the number of CD4+ T cells and ED3+
activated macrophages was seen in the intima.
After the first injury, a sustained elevation of PDGF-AA, PDGF-BB, and PDGF-Rß was
detected by immunohistochemistry in the media. Three days after the second injury,
higher levels of expression of PDGF-AA and PDGF-R were observed.
2. Inhibition of IGF-1 and PDGF receptors
2.1. Effect of administration of D-peptide analog of IGF-1 in rat carotid artery (II)
D-peptide analog of IGF-1, JB3, was used to determine the impact of inhibition of IGF-
1/IGF-1R interaction to lesion formation in rat carotid arteries. JB3 was administered as
a continuous subcutaneous infusion to rats over 14 d after carotid ballooning injury at
dosages of 10, 30 and 100 µg/kg/day. At dosages of 10 and 30 µg/kg/day, the compound
significantly reduced the number of proliferating neointimal cells as measured by 3H-
TdR incorporation. However, no significant effect was observed in intimal thickness 14
d after injury.
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2.2. PDGF-R tyrosine kinase inhibitor in rat carotid and aorta after single ballooning
injury (III)
Two PDGF-R tyrosine kinase inhibitors were used in order to study the effect of PDG-R
tyrosine kinase activation after ballooning injury, CGP 53716 and its water-soluble
derivative, CGP 57148B. Both of these compounds were shown to be specific inhibitors
of the PDGF-R tyrosine kinase.
CGP 53716 was administered to rats ip. once daily at a dose of 50 mg/kg/day. After
carotid denudation, CGP 53716 had no significant effect on the percentage of BrdU-
incorporating adventitial, medial or intimal cells, neither when the cells were labeled
during 0-72 or 72-96 postoperative hours. However, pulse labeling of the rats during the
final 93-96 hours before sacrifice showed a marginal inhibitory effect on the percentage
of BrdU-incorporating cells in the adventitia and media (p<0.05, Mann Whitney U test)
though not in the intima. On the other hand, migration of α-actin expressing SMC from
the media into the neointima during the time bracket of 72-96 hours was strongly
inhibited from 38±10 (n=18) to 4±2 (n=18) nuclei per vessel circumference (p<0.0001),
and there was a slight reduction in the number of cells in the adventitia and media
(p<0.05). After rat aorta denudation, a significant decrease in the number of intimal cells
and in the intima/media ratio was observed at 14 d (p=0.03).
2.3. PDGF-R tyrosine kinase inhibitor in ballooning reinjury of the rat aorta (V)
Finally, we investigated whether the enhanced proliferative response observed after
repeated ballooning injury to the rat aorta could be interfered with by inhibition of
PDGF-R tyrosine kinase. Peroral administration of the tyrosine kinase inhibitor CGP
57148B in vivo resulted in a 60% reduction both in the absolute number of BrdU+ cells
and the percentage of BrdU+ cells 3 d after the second ballooning injury, but had no
significant effect on proliferation after the first injury.
2.4. Inhibition of IGF-1 and PDGF receptors in vitro (II, III, V)
The D-peptide analog of IGF-1, JB3 inhibited the IGF-1-induced tyrosine
phosphorylation in primary rat aortic SMC at a concentration range of 0.1-10 µg/ml.
Maximal inhibition was seen at 1 µM concentration. Using Swiss 3T3 cells, shown to
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express PDGF-receptors, tyrosine kinase inhibitor CGP 57316 inhibited PDGF-induced
tyrosine phosphorylation of both receptor subtypes at an IC 50 value of approximately
0.03-0.1 µM.
In vitro, JB3 inhibited serum-induced primary rat aortic SMC 3H-TdR-incorporation in
a biphasic manner, maximally at a concentration of 1 µg/ml. CGP 53716 inhibited
PDGF-AA and PDGF-BB -induced 3H-TdR -incorporation and absolute cell numbers at
1 µM concentration dose-dependently. CGP 57148B selectively inhibited PDGF-AA
and PDGF-BB -induced proliferation at the optimal 1 µM concentration, whereas IGF-1
and bFGF -induced proliferation were unaffected.
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Figure 2. Summary of the major findings. (A) Recombinant human superoxide
dismutase -infusion during aortic graft reperfusion was inefficient in inhibiting
neointimal lesion formation in syngeneic aortic transplants. (B) After rat carotid
ballooning, inhibition of IGF-1R with the D-peptide analog JB3 led to a slight decrease
in lesion size possibly acting via inhibition in cellular proliferation, whereas inhibition
of the PDGF-R with the tyrosine kinase inhibitor CGP 53716 inhibited mainly cellular
migration. (C) After reinjury to rat aorta, a minimal apoptotic response was seen in the
neointima, followed by an enhanced proliferative and inflammatory response. PDGF-R
tyrosine kinase inhibitor CGP 5714BB inhibited this enhanced neointimal proliferation
and end-point lesion formation.
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DISCUSSION
1. The response-to-injury hypothesis
Neointimal formation and luminal occlusion of arteries is believed to be a pathological
response to endothelial injury (reviewed by Ross, 1993). In addition to pure mechanical
injury, caused by an angioplasty catheter, various other forms of injury can be identified
as initiators of neointimal lesion formation, such as reperfusion injury in bypass grafts or
organ transplants (Waltenberger et al., 1996), inflammation, infection (Koskinen et al.,
1993) and hyperlipidemia (Räisänen-Sokolowski et al., 1994), among other causes. The
similarity in lesion morphlogy in transplant arteriosclerosis, the fibrous atherosclerotic
plaques and restenotic arteries leads to the inevitable assumption that the pathogenesis
of these differentially primed disorders is the same. The current hypothesis is that
atherosclerotic and restenotic lesions constitute mainly of macrophages, T-cells and
myofibroblasts or SMC derived from adjacent tissues and circulation (Libby et al., 1992;
Ross, 1993).
2. Experimental models for studying vasculoproliferative disorders
Rat or rabbit aortic or carotid ballooning injury are widely used models to study the
mechanisms of SMC migration and proliferation in arteriosclerosis and restenosis.
These rodent models, however, are not to be applied directly to human settings of
restenosis, where various risk factors, such as individual susceptibility, gender, and other
factors are to be taken into account. Also, the protocol in human angioplasty always
involves antiplatelet/anticoagulant therapy, which in rats are usually not applied.
However, these rodent models allow us to study separately the cellular events after
endothelial injury in an in vivo environment, and allow us to exclude some of the
sources of error possible in in vitro models, such as cell differentiation/dedifferentiation
in vitro. Several agents have proved effective in animal models, such as angiotensin
converting enzyme inhibitors (Powell et al., 1989), angiotensin or its receptor  inhibitors
(Forney Prescott et al., 1991) and heparin (Rogers et al., 1996), have failed to be
effective in human studies (The MERCATOR Study Group, 1994; Ellis et al., 1989).
Some results, however, suggest that data derived from rodent models can be applicable
to human settings (Serruys et al., 1997): the efficacy of inhibition of neointimal
formation with PDGF inhibitors is mainly derived from studies made on rodents, and it
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has been shown that Trapidil, a specific PDGF inhibitor inhibits restenosis by as much
as 50% in humans (Maresta et al., 1994).
3. Neointimal smooth muscle cells
Evidently, rat models of arterioslerosis or restenosis differ from human lesions in many
respects: rats are very resistant to hypercholesterolaemia, so the lesions lack oxidised
low-density lipoproteins and foam cells. Mice defective in apolipoprotein E, are
spontaneously hypercholaesterolaemic and develop lesions rich in T cells and activated
macrophages (Lichtman et al., 1996; Zhou et al., 1996). In rodent models, after single
ballooning injury, the amount of inflammatory cell infiltrates and adhesion molecule
expression is not prominent with the possible exception of hyperlipidemic rabbits
(Tanaka et al., 1993). However, when reinjury is performed on a preformed neointima,
the lesion becomes rich in macrophages and T cells, suggesting that the response-to-
injury to a preformed neointimal layer is different from injury to an intact artery. A
functional difference in the first vs. the second injury has also been shown: antibodies to
bFGF and heparin, both well known inhibitors of proliferation after the first injury, do
not have an effect on proliferation after the second ballooning injury (Koyama and
Reidy, 1997), nor in human restenosis (see above and Mak and Topol, 1999).
Furthermore, we show in this study, that selective inhibition of PDGF-R is noneffective
in reducing proliferation after endothelial injury to intact rat aortas (first injury), whereas
after a second injury to preformed neointima, the same compound is highly efficient in
inhibiting neointimal proliferation.
Studies made with cloned SMC in vitro and cultured neointimal cells indicate that cells
of neointimal phenotype express  PDGF receptors and proteins differentially from
resting or contractile phenotype SMC (Lemire et al., 1994). Neointimal SMC resemble
SMC isolated from young rats: They represent a more primitive, dedifferentiated
phenotype expressing the PDGF-B gene but hardly any PDGF-Rα (Lemire et al., 1994).
Two recent studies show that PDGF selectively induces intimal proliferation without
having any effect on medial cell proliferation (Pompili et al, 1995; Sirois et al., 1997),
suggesting that the response of neointimal SMC to injury differs from the response of
medial SMC. Adding further evidence to the functional difference between injured
medial versus neointimal cells, we show in this study, that after repeated injury to rat
aorta, the enhanced proliferative response was linked to increased PDGF-AA, and
PDGF-Rß expression, and the inhibition of the PDGF-R had little effect on medial or
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neointimal SMC proliferation, but a pronounced effect on the proliferation of neointimal
cells after reinjury.
There is currently little information on the functional role of adhesion molecules in
SMC. It is classically thought that their primary role is to mediate leukocyte adhesion to
endothelial and SMC preceding local immune reactions (Libby et al., 1992). However,
more recent data suggests that these endothelial adhesion molecules are also expressed
in developmental stages of blood vessels (Couffinhal et al., 1994). Results presented in
this study show that the VCAM-1 adhesion molecule is expressed in SMC during and
shortly after proliferation has occurred. Very high levels of VCAM-1 were seen in SMC
3 d after injury in the medial cells, when high levels of proliferating cells are seen, but
practically no inflammatory cells were detected in the media during or following peak
VCAM-1 expression. Why would VCAM-1 be expressed in the media if its expression
is not linked with increased leukocyte adhesion? VCAM-1 is a marker for a
dedifferentiated SMC phenotype and may act as a receptor to extracellular matrix
components mediating cell adhesion; an absolute requirement for the migration and
proliferation of mesenchymal cells. Adhesion molecule P-selectin was also found to be
upregulated in regenerating endothelial cells. This upregulation may be linked to a more
efficient reqruitment of inflammatory cells to the neointima. P-selectin
immunoreactivity was also seen in platelets adherent to the internal elastic lamina after
balloon injury, possibly increasing leukocyte rolling/adhesion to sites of injury.
Recent studies have shown that endothelial cell progenitors can be isolated from the
peripheral blood, and that these cells contribute to angiogenesis (Asahara et al., 1997).
Others have shown that bone-marrow derived myogenic progenitor cells contribute to
the regeneration of striated muscle (Ferrari et al., 1998). Similarly, neointimal SMC
could originate from multipotent bone marrow stem cells via the circulation, which
could explain the phenotypic and functional differences in neointimal and medial SMC.
4. Inflammation in arteriosclerosis and restenosis
Monocytes and macrophages have been known to be present in arteriosclerotic lesions
both in classical atherosclerosis (Ross et al., 1984) and in transplant arteriosclerosis
(Rose and Uys, 1990). In vasculitis syndromes as well as in transplants undergoing
chronic rejection the correlation between inflammation and neointimal lesion formation
is a well-known late complication (Häyry et al., 1993; Somer, 1993). The role of
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inflammation, however, in lesions of classical atherosclerosis or restenosis may well
have been underestimated so far. Recently, epidemiological as well as experimental
evidence has been accumulating on the role of inflammation in atherosclerosis:
First, there has been epidemiological evidence on the association of chlamydia
pneumoniae (Saikku et al., 1988) and cytomegalovirus (Koskinen et al., 1993) to
atherosclerosis. Second, some of these micro-organisms have been detected in
neointimal lesions both in atherosclerotic (Kuo et al., 1993; Chiu et al., 1997) and
restenotic (Speir et al., 1994) lesions. Third, antibiotic treatment has in some studies
shown to decrease complications to acute myocardial infarction, suggesting an
infectious epidemiology to atherosclerosis (Gupta et al., 1997). It would be of interest to
find out, whether antibiotic or immunosuppressive treatment decreases the morbidity to
atherosclerosis by studying e.g., the incidence of coronary artery disease in  other than
heart transplant patients.
In this study, we show that the level of inflammatory cells increases after injury to
preformed neointima and hypothesize that expression of adhesion molecules in the
neointimal layer may lead to more efficient recruitment of leukocytes when this
preformed neointima is injured again.
5. Therapeutic strategies for vasculoproliferative disorders
Prolonged cold preservation is a risk factor for transplant arteriosclerosis. This is
believed to be due to the generation of toxic oxygen radicals. Independent of cold-
preservation/reperfusion -related free radical formation, oxidative processes are believed
to enhance atherosclerosis, although some controversy exists, whether antioxidants
prevent atherosclerosis (reviewed by Steinberg, 1995; Berliner and Heinecke, 1996).
We attempted to decrease cold-ischemia -induced injury in syngeneic rat aortic
transplants by perioperative administration of rh-SOD. No effect in atherosclerotic
lesion formation  in the transplanted grafts after 1-6 months was seen, whereas clinical
evidence upon the beneficial effects do exist (Land et al., 1994).
More than half of neointimal cells after a two-week observation time have migrated
there rather than derived from cell division (Clowes and Schwartz, 1985). So far, few
specific inhibitors of migration exist, and studies showing the effect of inhibition of
migration to final lesion formation are not many (Bendeck et al., 1996; Zempo et al.,
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1996). The mechanisms of migration and proliferation overlap in many respects, and the
same intracellular signaling cascades for migration and proliferation are used in cells.
The results presented here suggest that the mere inhibition of migration may suffice in
order to - at least partially - inhibit neointimal lesion formation. However, practically
nothing is known about the inhibition of migration in restenotic lesion formation or in
the reinjury models.
Although recent evidence suggests that proliferating cells are infrequently seen in
atherectomy specimens (O´Brien et al., 1993b) several histopathological findings from
restenosed arteries support a role for intimal proliferation in vessel occlusion (Essed et
al., 1983, Austin et al., 1985; Nobuyoshi et al, 1991). Some studies also suggest that
adventitial fibroblasts contribute to lesion formation after extensive ballooning injury
(Shi et al., 1996ab; Scott et al., 1996). This study among others (Koyama and Reidy,
1997; Stadius et al., 1996) shows that in rodents after reinjury of intima, proliferative
response is more rapidly downregulated and proliferating cells are not sustainedly seen
as they are after the first injury. It would, therefore, seem plausible that in human
lesions, high levels of proliferating cells would not be seen in mature restenotic lesions.
Controversially, in reinjury models, as well as in human restenosis neointimal size has
no correlation to luminal narrowing (Courtman et al, 1988; Andersen et al., 1996),
suggesting that the remodelling of blood vessels accounts for a compensatory
enlargement of the vessel lumen. Furthermore, increase in neointimal mass is not
correlated with an increase in cell numbers (Koyama and Reidy, 1988). Nevertheless,
after remodelling capacities of the blood vessel are lost, as in fibrosed human coronary
arteries subjected to angioplasty, neointimal proliferation and lesion formation evidently
leads to occlusion of artery and tissue hypoxia. Therefore, antiproliferative therapy
remains a plausible target for human restenosis.
6. Candidate drugs
It has been suggested that various proproliferative factors for SMC act via the
upreglation of IGF-1R and thus create an autocrine cycle that finally triggers cell cycle
progression to mitosis (Baserga, 1993). Findings made principally by Delafontaine and
colleagues using antisense oligonucleotides or antisera to the IGF-1R show that growth
induced by PDGF, angiotensin and thrombin at least are mediated by the IGF-1R
(Ververis et al., 1993; Delafontaine et al., 1996). These studies indicate that an IGF-
1/IGF-1R autocrine cycle is required for optimal growth of vascular SMC. Based on
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these findings, and on the upregulation of IGF-1R during SMC proliferation we
hypothezised that the D-peptide analog of IGF-1, JB3, could interfere with the
proliferative response to SMC after carotid ballooning injury, which, indeed, was the
case. The effect of inhibition of the IGF-1R has not previously been shown in vivo in
vascular proliferation. We were, however, unable to show that lesion size could actually
be affected by the inhibition of the IGF-1R in the rat carotid artery. This can partially be
due to the nature of the D-peptide analog as a competitive inhibitor, it may not inhibit
completely the activeation of the IGF-1R. Also, our findings suggest that inhibition in
proliferation may not sufffice for efficient inhibition of lesion formation.
Since migration of cells in as much as 50% is believed to contribute to neointimal lesion
formation (Clowes et al., 1983; Clowes and Swartz, 1985), the inhibition of migration
might therefore also be a requirement for optimal reduction in lesion formation after
ballooning injury. PDGF, on the other hand, has been shown to induce lesion formation
with a minor effect on cell proliferation in rat carotid artery (Ferns et al., 1991).
Therefore, inhibitor of the PDGF-R would in all likelihood inhibit migration but could
also affect proliferation possiby indirectly acting via the IGF-1R.
Highly selective receptor tyrosine kinase inhibitors have been developed (Levitzki and
Gazit, 1995; Levitzki, 1996). Nonselective tyrphostins have been shown to be inhibitory
to lesion formation in rat carotid artery (Golomb et al., 1996). Tyrphostins selective for
the PDGF-R have been shown to inhibit the formation of neointima in a porcine model
of restenosis when applied locally (Banai et al., 1998) supporting our concept of PDGF-
blockade as a treatment strategy for restenosis. Tyrphostin inhibitors for the IGF-1R that
have 100 times lower affinity to the highly homologous insulin receptor have been
developed 1 data strongly indicates that the development of even more selective receptor
tyrosine kinase inhibitors will soon be available for experimental animal and human
studies. Specific inhibitors of the IGF-1R would be extremely interesting to test in
models of vascular proliferation, since e.g. peptide analogs have the disadvantage of
being difficult to produce and their administration as a continuous infusion is
suboptimal.
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SIGNIFICANCE OF FINDINGS
This study supports the accumulating amount of evidence indicating that neointimal
SMC differ from resting, medial SMC in their ability to proliferate in response to injury,
in their activation state and response to PDGF-R activation. Also, this study is the first
one to show that neointimal cells are more resistant to programmed cell death than
medial SMC - a finding which may also be helpful in understanding the pathogenesis of
restenosis. Inhibition of IGF-1 or PDGF receptors can be used as therapeutic strategies
in the inhibition of vasculoproliferative disorders such as restenosis after coronary
angioplasty. More detailed studies in large animal models or human trials will
eventually show whether this approach could also be used in treatment of human
restenosis.
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SUMMARY
The thickening of the innermost layer of arteries, the neointima, and remodelling of the
vascular wall are the principal pathogeneic mechanisms underlying atherosclerosis,
restenosis and transplant arteriosclerosis. Injury to arteries - regardless of its cause -
leads to proliferation of SMC in the medial (muscular) layer, and the subsequent
migration of these cells into the neointima, where they start by proliferating to form the
neointimal layer.
The first objective of this study was to investigate the formation of arteriosclerotic
lesions using experimental animal and in vitro models, as well as to develop more
suitable models for studying the mechanisms of restenosis.The second objective in this
study was to prevent pharmacologically neointimal formation and thickening of arteries
using specific inhibitors of the IGF-1 and PDGF receptors. Three rat models were used
for studying neointimal lesion formation: cold-ischemia-induced arteriosclerosis, carotid
artery ballooning injury, and ballooning reinjury of the rat aorta. Quantitative studies on
SMC migration and proliferation were performed using SMC cultures.
The results showed that all experimental models induced severe arteriosclerosis-like
changes, with the common feature of SMC-rich neointimal lesions. We demonstrated
that in cold-ischemia -induced arteriosclerosis, and after  ballooning injury of the rat
carotid artery, upregulation of several peptide growth factors was observed during lesion
formation. The results indicated that the local production of growth factors may
contribute to neointimal formation. When ballooning injury was performed on a pre-
existing neointimal lesion, as is done in human angioplasty operations, we were able to
show that the proliferative and apoptotic response, and the cellular composition differed
significantly from a lesion induced by a single ballooning injury to rat arteries.
We then studied the effect of blocking some of these upregulated growth factors in
lesion formation in rat carotid artery after injury. Using a stable D-peptidic analog of
IGF-1, we were able to inhibit neointimal SMC proliferation in rat carotid artery. Using
a selective inhibitor of the PDGF-R an effect was seen primarily in SMC  migration and
at the increase in lesion size at the end point of observation. Finally, we were able to
inhibit the enhanced proliferative response after ballooning reinjury by a specific
inhibitor of the PDGF-R.
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The results of this study indicate that IGF-1 and PDGF are major regulators of SMC
migration and proliferation in vivo. We also show that neointimal SMC are more
resistant to programmed cell death than medial SMC, and respond differentially to the
inhibition of PDGF-R. The findings may be useful in the understanding of the
pathogenesis of restenosis after angioplasty. Inhibition of PDGF-R can have clinical
applications in the preventive therapy for restenosis.
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YHTEENVETO (FINNISH SUMMARY)
Valtimoiden sisäseinämän paksuuntuminen aiheuttaa verisuonen ahtautumisen
valtimoiden kovettumataudin varhaisessa vaiheessa ja sepelvaltimoiden
pallolaajennuksen jälkeisessä uudelleenahtautumisessa, restenoosissa. Restenoosi on
yleinen komplikaatio onnistuneen pallolaajennuksen jälkeen; n. 30-40%
pallolaajennetuista sepelvaltimoista ahtautuu uudelleen puolen vuoden sisällä
operaatiosta.
Verisuonten sisäpintaa verhoavan endoteelisolukon vaurio johtaa yleensä sileän
lihassolukon jakautumiseen valtimoiden keski- eli lihaskerroksessa. Osa näistä
jakautuneista lihassoluista migroituu sisäseinämän puolelle ja jakautuu edelleen
ahtauttaen suonta. Endoteelivaurion aiheuttaja voi olla mekaaninen
(pallolaajennuskatetri), immunologinen (elinsiirrännäiseen kohdistuva hyljintäreaktio)
tai oksidaation aiheuttama (reperfuusiovaurio tai hapettuneen LDL:N kertyminen
verisuoneen). Riippumatta endoteelivaurion laadusta, valtimoiden ahtautumiseen
johtavat sileälihassoluvasteiden mekanismit ovat hyvin pitkälle samankaltaisia.
Väitöskirjatyön tarkoituksena oli tutkia kokeellissa eläinmalleissa tapahtuvaa
verisuonivaurion jälkeistä jakautumis- ja migraatiovastetta sekä kehittää restenoosin
mekanismien tutkimiseen soveltuva koe-eläinmalli. Lisätavoitteena oli vähentää
verisuonen sisäseinämän kasvua farmakologisesti estämällä  insuliinin kaltaisen
kasvutekijän (IGF-1) ja verihiutaleperäisen kasvutekijän (PDGF, platelet-derived growth
factor) toiminta.
Tutkimusmenetelminä kaytettiin kolmea erilaista kokeellista rottamallia:
kylmäiskeamian indusoimaa ateroskleroosia, rotan kaulavaltimon pallolaajennuksen
aiheuttamaa ateroskleroosia ja rotan aortan kaksoisvauriomallia (restenoosin mallina).
Soluviljelmässä tutkittiin lääkeaineiden vaikutusta sileän lihassolukon migraatioon ja
jakautumiseen ennen lääkkeiden testaamista koe-eläimessä.
Tutkimustulokset osoittavat, että kaikissa kokeellisissa malleissa verisuoniin kehittyy
ensisijaisesti sileästä lihassolukosta koostuva sisäseinämän paksuuntuma. Lisäksi
tulokset osoittivat, että verisuonen seinämän kasvutekijätuotanto lisääntyy solujen
jakautuessa ja vaurion kehityessä. Kasvutekijöillä oli vaikutusta ahtauman
muodostumiseen: estämällä IGF-1:n sitoutuminen reseptoriinsa sen D-peptidianalogilla
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(kompetitiivinen inhibitio), sileän lihassolukon jakautumisvaste estyi n. 50 %:sti.
Vaikutus valtimon sisäseinämän paksuuntumiseen oli kuitenkin vähäinen. Estämällä
PDGF-reseptorin aktivoivan tyrosiinikinaasin toiminta valtimon sileälihassolukon
migraatio estyi n. 90%:lla ja sisäseinämän paksuuntuminen estyi 40%:lla.
Valtimoiden pallolaajennuksen jälkeisen uudelleenhtautumisen, restenoosin tutkimiseksi
kehitimme rotan aortan kaksoisvauriomallin. Tällä mallilla osoitettiin, että
jakautumisvaste vaurioitettaessa jo ahtautunutta suonta eroaa huomattavasti vauriosta
terveeseen suoneen: jakautumisvaste on nopeampi ja voimakkaampi. Osoitimme myös,
että sisäseinämän solut ovat resistenttejä vaurion aiheuttamalle ohjelmoidulle
solukuolemalle verrattaessa lihassolukerroksen soluihin. Nopea sileän lihassolukon
jakautumisvaste ja ahtauman muodostaminen on estettävissä estämällä PDGF-reseptorin
toiminta.
Väitöskirjassa osoitettiin, että valtimon sisäseinämän solut ovat resistentimpiä
ohjelmoidulle solukuolemalle kuin lihassolukerroksen solut, mikä selittää
pallolaajennuksen jälkeisen valtimoiden uudelleenahtautumisen patogeneesiä. IGF-1 ja
PDGF -kasvutekijäreseptorit ovat merkittäviä sileän lihassolukon kasvun säätelijöitä
valtimoissa in vivo. PDGF-reseptorien estäjillä saattaa tulevaisuudessa olla huomattava
kliininen ja taloudellinen merkitys restenoosin ennaltaehkäisevässä hoidossa.
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SAMMANDRAG (SWEDISH SUMMARY)
Skada mot endotelcellagret, dvs. det innersta cellagret i artärer leder till
blodkärlsförtjockning. Förtjockningen beror på att glatta muskelceller (GMC) från
blodkärlets mellersta del (tunica media) migrerar till den inre delen (tunica intima) och
prolifererar däri. Migration och proliferation av glatt muskelvävnad är den principiella
mekanismen bakom restenos, dvs. en upprepad förträngning av koronärartärer, som sker
efter koronärangioplasti i 50-80% av fallen. Oberoende av endotelskadans orsak, som
kan vara mekanisk, (angioplastikateters in koronarangioplasti), immunologiskt
(rejektion i transplanterade organ, eller en frigörelse av fria syreradikaler
(reperfusionskada), är mekanismen bakom GMC migrationen och proliferationen
densamma. Det har visats att att det finns flera tillväxtfaktorer för GMC, av vilka är en
av de mest undersökta insulin-liknande tillväxtfaktorn IGF-1, och blodtillväxtfaktorn,
PDGF (platelet-derived growth factor). Tillsvidare finns det inga effektiva läkemedel för
att förebygga restenos eller transplantationsateroskleros.
Avsikten med denna undersökning var att studera blodkärlsförtjockning i
försöksdjurmodeller. Vi ville också utveckla en lämpligare försöksdjursmodell för att
studera restenos. Avsikten var också att farmakologiskt förebygga åderförtjockning
genom att hämma IGF-1 och PDGF -receptorer hos försöksdjur.
Ballongangioplasti är mycket använd i försöksdjursmodeller för att studera okklusion av
artärer. En ballongskada skapas mot råttans halsartär eller aorta. I undersökningen har
tre olika metoder använts för att studera ocklusion i artärer efter endotelskada:
kalliskemi-inducerad ateroskleros, ballongskada mot råttans halsartär eller aorta, och
dubbelballongskada mot råttans aorta. Migration och proliferation av glatta muskelceller
och inverkan av läkemedel studerades i dessa modeller samt i cellkulturer.
Resultaten visade, att i alla dessa modeller består de förtjockade artärerna av GMC. Vi
visade ochså, att att när cellerna delar sig, ökar tillväxtfaktorproduktionen i blodkärlen,
vilket tyder på att tillväxtfaktorerna har betydelse i åderhyperplasi. Vi visade även, att
när man hämmar IGF-1 genom att binda receptoren med IGF-1 D-peptidanalog, är det
möjligt att minska GMC proliferation med 50%. Inverkan på åderhyperplasi var mindre.
Genom att hämma PDGF-receptoraktivationen med en tyrosinkinashämmare, var det
möjligt att minska migration av GMC med 90%, och åderhyperplasi med 40%.
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En av de största nackdelar i ballongskademodellerna är, att skadan förorsakas på en
intakt artär. Som terapeutisk åtjärd görs interventionerna däremot alltid på en förtjockad
eller sklerotiskt artär. Genom att skada råttans aorta två gånger med två veckors
mellanrum har vi kunnat påvisa, att den proliferativa responsen mot en upprepad
ballongskada inträffar betydligt snabbare och är mera intensiv jämfört med responsen
vid skada mot en intakt artär. Vi visade också, att GMC i intima är mera resistenta för
apoptos efter ballongskada, än vad GMC i media är.
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